APP and Alzheimer disease: Furthermore, DMB treatment managed to reduce hippocampal neuroinflammation and AD-associated pathologies like Aβ42, β-secretase and βCTF (β-secretase-cleaved C-terminal fragment) levels in APP/PS1 mice [191].